公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2010 | HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses | Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN ; JIA-HORNG KAO ; Lai M.-Y.; CHEN-HUA LIU ; TUNG-HUNG SU ; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN ; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Infectious Diseases | 42 | 37 | |
2002 | Hepatitis B e antigen and the risk of hepatocellular carcinoma | Yang H.-I.; Lu S.-N.; Liaw Y.-F.; You S.-L.; Sun C.-A.; Wang L.-Y.; CHUHSING KATE HSIAO ; PEI-JER CHEN ; Chen D.-S.; Chen C.-J. | New England Journal of Medicine | 1090 | 938 | |
2017 | Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study | TAI-SHUAN LAI ; Lee M.-H.; Yang H.-I.; You S.-L.; Lu S.-N.; Wang L.-Y.; Yuan Y.; L'Italien G.; KUO-LIONG CHIEN ; Chen C.-J.; the REVEAL-HCV Study Group | Hepatology | 57 | 52 | |
2020 | Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan | Wang J.-H.; CHIEN-HUNG CHEN ; Chang C.-M.; Feng W.-C.; Lee C.-Y.; Lu S.-N. | Journal of the Formosan Medical Association | 13 | 10 | |
2010 | Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study | Lee M.-H.; Yang H.-I.; Lu S.-N.; Jen C.-L.; Shiou-Hwei Yeh ; CHUN-JEN LIU ; PEI-JER CHEN ; You S.-L.; Wang L.-Y.; WEI J. CHEN ; Chen C.-J. | Journal of Clinical Oncology | 143 | 131 | |
2017 | High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease | TAI-SHUAN LAI ; Lee M.-H.; Yang H.-I.; You S.-L.; Lu S.-N.; Wang L.-Y.; Yuan Y.; L'Italien G.; KUO-LIONG CHIEN ; Chen C.-J.; REVEAL-HCV Study Group | Kidney International | 27 | 26 | |
2021 | How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers? | Chen M.-H.; Lu S.-N.; CHIEN-HUNG CHEN ; Lin P.-C.; Jiang J.-K.; D’yachkova Y.; Lukanowski M.; Cheng R.; Chen L.-T. | Cancers | 2 | 1 | |
2009 | Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation | Chiang J.-C.; Lin C.-Y.; Wang J.-H.; Kee K.-M.; Chen P.-F.; Chen Y.-D.; Tsai L.-S.; Chen, Tony Hsiu Hsi ; Lu S.-N. | Transactions of the Royal Society of Tropical Medicine and Hygiene | 4 | 3 | |
2019 | Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients | Hu H.-H.; Liu J.; Chang C.-L.; Jen C.-L.; Lee M.-H.; Lu S.-N.; Wang L.-Y.; Quan Y.; Xia N.-S.; Chen C.-J.; PEI-JER CHEN ; Yang H.-I. | Clinical Gastroenterology and Hepatology | 20 | 17 | |
2011 | Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses | Yeh M.-L.; Hung C.-H.; Huang J.-F.; CHUN-JEN LIU ; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | PLoS ONE | 19 | 15 | |
2006 | Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan | CHIEN-HUNG CHEN ; Su W.-W.; Yang S.-S.; Chang T.-T.; Cheng K.-S.; Lin H.H.; Wu S.-S.; Lee C.-M.; Changchien C.-S.; Chen C.-J.; JIN-CHUAN SHEU ; DING-SHINN CHEN ; Lu S.-N. | Journal of Gastroenterology and Hepatology (Australia) | 53 | 53 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2014 | Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan | CHI-LING CHEN ; WEI-SHIUNG YANG ; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; CHUN-JEN LIU ; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN ; Chen C.-J. | Cancer Epidemiology Biomarkers and Prevention | 19 | 16 | |
2015 | A polymorphism in interferon L3 Is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis c virus infection | Chang K.-C.; Tseng P.-L.; Wu Y.-Y.; Hung H.-C.; Huang C.-M.; Lu S.-N.; Wang J.-H.; Lee C.-M.; Chen C.-H.; Tsai M.-C.; Yen Y.-H.; Lin M.-T.; Wu C.-K.; Huang C.-C.; Chen, Tony Hsiu Hsi ; Hu T.-H. | Clinical Gastroenterology and Hepatology | 49 | 47 | |
2015 | Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system | Liu J.; TAI-CHUNG TSENG ; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; PEI-JER CHEN ; Chen C.-J.; JIA-HORNG KAO | Journal of Infectious Diseases | 16 | 13 | |
2013 | A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection | Liu J.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Iloeje U.H.; Lu S.-N.; Wang L.-Y.; You S.-L.; CHUHSING KATE HSIAO ; Yang H.-I.; Chen C.-J. | Journal of Hepatology | 81 | 69 | |
2010 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients | Yang T.-S.; Lu S.-N.; Chao Y.; Sheen I.-S.; Lin C.-C.; Wang T.-E.; Chen S.-C.; Wang J.-H.; Liao L.-Y.; Thomson J.A.; Wang-Peng J.; PEI-JER CHEN ; Chen L.-T. | British Journal of Cancer | 134 | 124 | |
2013 | Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia | Chen D.-S.; Locarnini S.; Wait S.; Bae S.-H.; PEI-JER CHEN ; Fung J.Y.Y.; Kim H.S.; Lu S.-N.; Sung J.; Tanaka J.; Wakita T.; Ward J.; Wallace J. | Journal of Hepatology | 22 | 23 | |
2006 | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level | Chen C.-J.; Yang H.-I.; Su J.; Jen C.-L.; You S.-L.; Lu S.-N.; GUAN-TARN HUANG ; Iloeje U.-H.; REVEAL-HBV Study Group | Journal of the American Medical Association | 2634 | 2370 | |
2020 | Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | Huang Y.-W.; Hsu C.-W.; Lu S.-N.; Yu M.-L.; Su C.-W.; Su W.-W.; Chien R.-N.; Hsu C.-S.; SHIH-JER HSU ; Lai H.-C.; Qin A.; Tseng K.-C.; PEI-JER CHEN | Hepatology International | 18 | 14 |